NAD+ for Weight Loss: What the Peer-Reviewed Evidence Actually Says About NMN, NR, and IV NAD+ Drips

TL;DR

NAD+ supplements and IV NAD+ drips have no peer-reviewed RCT evidence for weight loss in humans. The flagship human metabolic trial — Yoshino M 2021 (PMID 33888596, Science) — gave 25 prediabetic postmenopausal women 250 mg/day of nicotinamide mononucleotide (NMN) or placebo for 10 weeks. The trial demonstrated improved muscle insulin sensitivity but reported no significant change in body weight, body fat, lean mass, or waist circumference.

Two nicotinamide riboside (NR) trials reach the same null conclusion on body composition. Martens CR 2018 (PMID 29599478, Nature Communications) tested 1,000 mg/day NR for 6 weeks in healthy middle-aged and older adults: no significant body composition change. Dollerup OL 2018 (PMID 29992272, American Journal of Clinical Nutrition) tested 2,000 mg/day NR for 12 weeks in obese, insulin-resistant men: no improvement in body composition, insulin sensitivity, or hepatic lipid content.

IV NAD+ drips ($200–$500 per session) have zero peer-reviewed RCT evidence for weight loss. No published randomized controlled trial has demonstrated meaningful weight change from IV NAD+ infusion at any dose, frequency, or duration. The wellness-clinic marketing of IV NAD+ for “metabolism boost,” “fat oxidation,” or “weight loss” exceeds what published evidence supports.

FDA has not approved NAD+ or any precursor for any weight-loss indication. The FDA's November 2022 NDI/IND-exclusion ruling effectively removed NMN from the US dietary supplement marketplace because NMN had been authorized for new-drug investigation before being marketed as a supplement; under DSHEA, that prior drug-investigation status excludes a substance from sale as a dietary supplement. NR remains commercially available.

Real weight loss requires sustained caloric deficit + adequate protein (1.2–1.6 g/kg/day per ACSM and ISSN) + exercise + — for qualifying patients — FDA-approved anti-obesity medications:

• Wegovy (semaglutide) produces ~15% total body weight loss in STEP-1 (Wilding 2021, PMID 33567185, NEJM) over 68 weeks
• Zepbound (tirzepatide) produces ~21% TBWL in SURMOUNT-1 (Jastreboff 2022, PMID 35658024, NEJM) over 72 weeks
• Saxenda, Foundayo, and ASMBS bariatric surgery have similarly documented magnitudes

For context: the largest documented effect of NAD+ supplementation on weight in human RCTs is zero kilograms. The order-of-magnitude gap between the published NAD+ weight-loss effect (null) and FDA-approved AOM effect (14–20 kg over 68–72 weeks) is not a small gradient — it is the difference between an unproven intervention and a clinically validated one.

For our broader evidence-graded review of weight-loss supplements covering berberine, ashwagandha, chromium, green tea catechins, and more, see our hub article Supplements for weight loss on GLP-1: evidence-graded review. This article is the keyword-specific deep-dive on the NAD+ family (oral NMN, oral NR, IV NAD+).

1. What NAD+ actually is

NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme present in every cell of the body. Without it, cellular metabolism stops. NAD+ participates in hundreds of biochemical reactions, but three categories dominate its biological importance:

• Oxidative phosphorylation: NAD+/NADH redox cycling in mitochondria is the central electron-carrier mechanism that powers ATP production. Without NAD+, the electron transport chain cannot function and cells cannot produce energy aerobically.
• DNA repair via PARPs: Poly(ADP-ribose) polymerase enzymes use NAD+ as a substrate to mark and repair DNA damage. PARP activity rises sharply under DNA-damage stress and consumes large amounts of cellular NAD+.
• Gene regulation via sirtuins: Sirtuin-family deacetylase enzymes (SIRT1–SIRT7) use NAD+ as a cofactor to remove acetyl groups from histones and other proteins, regulating gene expression, mitochondrial biogenesis, and stress responses. SIRT1 and SIRT3 are the most-studied in the metabolic-aging literature.

NAD+ is synthesized in the body from dietary precursors via three primary biosynthetic pathways: (1) de novo from tryptophan via the kynurenine pathway; (2) from niacin (nicotinic acid, vitamin B3) via the Preiss-Handler pathway; and (3) from nicotinamide (NAM) and nicotinamide riboside (NR) via the salvage pathway. The salvage pathway is the dominant route in most tissues and is the route exploited by commercial NMN and NR supplements (Rajman L 2018, PMID 29514064, Cell Metabolism).

Age-related NAD+ decline. Animal studies have consistently documented declines in tissue NAD+ levels with aging. Human evidence is less consistent and more tissue-specific; broad-stroke claims that “NAD+ falls 50% by age 50” commonly cited in supplement marketing are extrapolations from animal models and isolated human studies, not consensus quantification. The hypothesis that restoring NAD+ levels with supplementation would reverse aspects of age-related metabolic decline drove the development of NMN and NR as commercial products and is reviewed in Rajman 2018 (PMID 29514064, Cell Metab) and Yoshino J 2018 (PMID 29249689, Cell Metab).

The biological plausibility is reasonable. The translation from cellular biochemistry to clinically meaningful weight loss is what the human RCTs do NOT support, as Sections 3 and 4 detail.

2. Oral precursors (NMN, NR) vs IV NAD+ — what consumers actually buy

Three product categories dominate the consumer NAD+ marketplace:

2.1 Oral nicotinamide mononucleotide (NMN)

NMN is the direct biochemical precursor to NAD+ in the salvage pathway. Sold as capsules or sublingual tablets at doses of 250–1,000 mg/day. Cost: typically $50–$120 per month when commercially available. Studied in humans by Yoshino M 2021 (PMID 33888596, Science), Irie 2020 (PMID 31685720, Endocrine Journal, Japanese men pharmacokinetics), and Liao 2021 (PMID 34238308, Journal of the International Society of Sports Nutrition, aerobic capacity in amateur runners).

FDA regulatory status: in November 2022, the FDA issued a determination that NMN is excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(ii) of the Federal Food, Drug, and Cosmetic Act, because NMN had been authorized for investigation as a new drug before being marketed as a supplement. Under DSHEA, that prior drug-investigation authorization removes NMN from the dietary supplement marketplace. The practical effect: NMN can no longer be lawfully sold as a dietary supplement in the US. Some products marketed online may technically violate this ruling; some have rebranded as “research chemicals” or shifted to non-US fulfillment.

2.2 Oral nicotinamide riboside (NR)

NR is one step further upstream than NMN in the salvage pathway — cells convert NR to NMN, which is then converted to NAD+. Sold as capsules under brand names including Niagen and Tru Niagen at doses of 250–1,000 mg/day. Cost: typically $40–$80 per month. Studied in humans by Martens CR 2018 (PMID 29599478, Nat Commun, healthy middle-aged and older adults), Dollerup 2018 (PMID 29992272, Am J Clin Nutr, obese insulin-resistant men), Dellinger 2017 (PMID 29184669, NPJ Aging Mech Dis, safety pharmacokinetics of NR+pterostilbene), and Trammell SA 2016 (PMID 27721479, Nat Commun, oral bioavailability and metabolism).

FDA regulatory status: NR remains commercially available as a dietary supplement in the US. Niagen (ChromaDex) holds New Dietary Ingredient (NDI) notification status with the FDA and Generally Recognized as Safe (GRAS) self-affirmation for specified uses.

2.3 IV NAD+ drips

IV NAD+ infusion delivers NAD+ directly into the bloodstream, bypassing oral absorption. Typical wellness-clinic protocols infuse 250–1,000 mg of NAD+ over 2–4 hours, often weekly or monthly. Cost: $200–$500 per session. Annual cost at weekly infusion: $10,400–$26,000. Annual cost at monthly infusion: $2,400–$6,000.

FDA regulatory status: IV NAD+ is not FDA-approved for any indication. It is typically prepared by compounding pharmacies and administered at wellness clinics, medical spas, or concierge IV therapy practices. The compounded-IV regulatory framework provides limited FDA oversight compared to FDA-approved drug products.

2.4 Pharmacokinetic comparison

Oral NMN and NR both elevate blood and tissue NAD+ levels in healthy adults when taken at studied doses. Trammell 2016 (PMID 27721479, Nat Commun) characterized oral NR metabolism in humans and demonstrated dose-dependent increases in blood NAD+ markers. Irie 2020 (PMID 31685720, Endocrine Journal) characterized oral NMN pharmacokinetics in healthy Japanese men — single doses of 100, 250, and 500 mg were absorbed and metabolized predictably with no adverse effects reported.

IV NAD+ infusion produces high transient blood NAD+ levels but the published human pharmacokinetics, distribution to specific tissues, and durability of cellular NAD+ elevation are not well-characterized in peer-reviewed literature relative to the oral precursors.

The critical point for weight-loss claims: elevating blood NAD+ levels is NOT the same as causing weight loss. The trials that measured body composition outcomes (Yoshino M 2021, Martens 2018, Dollerup 2018) all confirmed NAD+ elevation while simultaneously reporting no meaningful weight change.

3. The published human RCTs: what they actually measured and what they actually found

Four published human randomized controlled trials (and one safety trial) represent the bulk of peer-reviewed evidence for NAD+ precursor supplementation in humans relevant to metabolic outcomes. All were verified live via PubMed E-utilities on 2026-05-15.

3.1 Yoshino M 2021 (Science) — NMN in prediabetic women

Citation: Yoshino M, Baur JA, Imai SI, et al. “Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.” Science (2021), PMID 33888596.

Design: 25 prediabetic, postmenopausal women with overweight or obesity were randomized to oral NMN 250 mg/day or placebo for 10 weeks in a double-blind placebo-controlled trial conducted at Washington University School of Medicine.

Primary outcome: muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp with a glucose tracer.

Findings: NMN produced a statistically significant 25% improvement in muscle insulin sensitivity compared with placebo. This is a real cellular metabolic change.

Critical for the weight-loss claim: the trial also measured body weight, body fat percentage, lean mass, and waist circumference as secondary endpoints. No significant differences were observed between the NMN and placebo groups on any of these body composition measures. Whole-body insulin sensitivity, hepatic insulin sensitivity, and adipose tissue insulin sensitivity were also unchanged.

Practical translation: NMN can improve a specific cellular biomarker (muscle insulin sensitivity) without producing weight loss. The supplement marketing claim that NMN “boosts metabolism” or “causes fat loss” in humans is not supported by this trial — the most-cited human NMN metabolic study to date.

3.2 Martens CR 2018 (Nature Communications) — NR in healthy older adults

Citation: Martens CR, Denman BA, Mazzo MR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nature Communications (2018), PMID 29599478.

Design: 30 healthy middle-aged and older adults (55–79 years) randomized to oral NR 500 mg twice daily (1,000 mg/day total) or placebo for 6 weeks in a crossover trial.

Primary outcomes: blood NAD+ metabolome, safety, tolerability, and cardiovascular markers.

Findings: NR was safe and well-tolerated, elevated blood NAD+ levels by approximately 60%, and produced modest reductions in systolic blood pressure and arterial stiffness in subgroup analyses.

Critical for the weight-loss claim: body composition (weight, BMI, waist circumference, body fat percentage) was assessed and no significant change was observed. The trial was not powered as a weight-loss study, but the data are consistent with the broader pattern: NR can elevate NAD+ levels without producing weight loss.

3.3 Dollerup OL 2018 (Am J Clin Nutr) — NR in obese insulin-resistant men

Citation: Dollerup OL, Jørgensen SB, Trammell SA, et al. “A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.” American Journal of Clinical Nutrition (2018), PMID 29992272.

Design: 40 men with obesity and insulin resistance randomized to oral NR 2,000 mg/day or placebo for 12 weeks in a parallel-group double-blind RCT — the most directly relevant trial to consumer weight-loss claims because the population is the target population (men with obesity), the dose is at the higher end of commercial recommendations, and the duration matches typical supplement-trial durations.

Primary outcomes: insulin sensitivity (hyperinsulinemic-euglycemic clamp), body composition (DXA), hepatic and intramyocellular lipid content (MRS).

Findings: 12 weeks of NR supplementation at 2,000 mg/day did NOT improve insulin sensitivity, did NOT change body composition, did NOT alter hepatic or intramyocellular lipid content, and did NOT improve any measured metabolic outcome compared with placebo. NR was safe and well-tolerated.

Critical for the weight-loss claim: this is the single most-relevant trial to the consumer weight-loss-supplement marketplace. The target population (obese men), the studied dose (2,000 mg/day), the studied duration (12 weeks), and the studied outcomes (body composition, insulin sensitivity, hepatic lipid) all match the marketing claims for NAD+ supplements. And the result was completely null on every measured endpoint.

Marketers of NMN and NR supplements rarely cite Dollerup 2018. This is the trial they need to cite, and the one that most directly refutes the weight-loss claim.

3.4 Dellinger 2017 (NPJ Aging Mech Dis) — NR safety/pharmacokinetics

Citation: Dellinger RW, Santos SR, Morris M, et al. “Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study.” NPJ Aging and Mechanisms of Disease (2017), PMID 29184669.

Design: 8-week safety and dose-escalation study of an NR+pterostilbene combination supplement (NRPT) in 120 healthy adults.

Primary outcome: safety, tolerability, durable NAD+ elevation.

Findings: NRPT was safe, well-tolerated, and sustainably elevated blood NAD+ levels over 8 weeks. This trial established the safety basis for ongoing NR supplementation but did NOT measure weight loss as a primary or secondary endpoint.

Practical takeaway: short-term NR supplementation at studied doses is safe. Safety does NOT imply efficacy for weight loss.

3.5 Other human evidence

Liao 2021 (PMID 34238308): randomized trial of NMN in 48 amateur runners examining aerobic capacity over 6 weeks. Found dose-dependent improvements in aerobic capacity measures with NMN supplementation. Weight and body composition were not the primary endpoints; no significant weight change was reported.

Trammell SA 2016 (PMID 27721479): characterized NR oral bioavailability and metabolism in humans. A pharmacokinetic study, not a weight-loss trial.

Irie 2020 (PMID 31685720): oral NMN pharmacokinetics in 10 healthy Japanese men at single doses of 100, 250, and 500 mg. Confirmed oral absorption and metabolism; no adverse events. A pharmacokinetic study, not a weight-loss trial.

3.6 Mills KF 2016 — the preclinical mouse study

Marketing of NMN often cites Mills KF 2016 (PMID 28068222, Cell Metabolism), which examined long-term NMN administration in mice and found benefits on age-related physiological decline including improved energy metabolism, insulin sensitivity, and physical activity in aged mice. This is an animal study, not human evidence. Mouse metabolic outcomes do not reliably translate to humans — this is one of the most consistent observations across the entire dietary supplement literature. Citation of Mills 2016 as evidence for human weight loss is a category error.

4. Why metabolic markers improve but weight does not

The Yoshino 2021 finding — improved muscle insulin sensitivity with no body weight change — is the textbook example of a recurring pattern in supplement research: positive cellular mechanism marker, null clinical outcome.

Three reasons this pattern is common and predictable:

(1) Cellular metabolism is not net caloric balance. Body weight is governed by caloric intake versus caloric expenditure over time. Cellular insulin signaling improvements do NOT automatically reduce appetite, change food preferences, or burn enough additional calories to produce measurable weight change in free-living adults. A 25% improvement in muscle insulin sensitivity is metabolically meaningful for glucose disposal but corresponds to a trivial increase in resting energy expenditure — nowhere near enough to drive measurable weight loss without diet/exercise change.

(2) Compensatory behaviors offset cellular improvements. Even if NAD+ supplementation increased energy expenditure slightly, free-living humans tend to compensate by reducing voluntary activity (less fidgeting, less spontaneous movement, slightly more sedentary behavior) or by increasing food intake to match the additional caloric demand. The net effect on body weight approaches zero.

(3) The magnitude of effect is too small to detect at study sizes and durations. Even if NAD+ supplementation produced a small real weight effect (say 0.5–1.0 kg over 12 weeks), trials with 25–40 participants over 6–12 weeks are statistically underpowered to detect such effects against the noise of weight fluctuation in free-living adults. The Dollerup trial (n=40, 12 weeks, 2,000 mg/day) had the best chance of detecting an effect of this magnitude and still reported no significant change.

For contrast: STEP-1 (semaglutide in obesity, PMID 33567185) enrolled 1,961 participants for 68 weeks and reported a mean weight reduction of 14.9% in the active arm versus 2.4% in placebo — a 12.5-percentage-point difference, unambiguous, and detected with vast statistical power. SURMOUNT-1 (tirzepatide in obesity, PMID 35658024) enrolled 2,539 participants for 72 weeks and reported up to 20.9% TBWL in the active arm versus 3.1% in placebo — a 17.8-percentage-point difference. These are the magnitudes of effect at which weight-loss interventions deserve consideration. NAD+ supplementation does not produce effects in this range.

5. IV NAD+ drips: marketing vs evidence

IV NAD+ infusion has become a high-revenue category in the wellness-clinic, medical-spa, and concierge IV therapy industries. Typical pricing: $200–$500 per session, with most clinics recommending weekly or monthly protocols. Some packages bundle 4–6 sessions at a discount and run $1,500–$3,000.

The marketed claims: “longevity,” “metabolism boost,” “fat oxidation,” “energy,” “mental clarity,” “addiction recovery,” “brain fog,” “jet lag,” and — for the weight-loss audience — “burns fat,” “increases metabolism,” “supports weight management.”

The published evidence: zero peer-reviewed randomized controlled trials have demonstrated weight loss from IV NAD+ infusion in humans. A 2026 PubMed search for IV NAD+ combined with weight, body composition, BMI, body fat, or obesity returns no positive RCT evidence supporting the weight-loss claims. The IV NAD+ literature is dominated by (1) case reports of use in addiction recovery, (2) uncontrolled wellness-clinic patient series, and (3) mechanistic and animal studies. None of these is competent scientific evidence for the consumer weight-loss claims being marketed.

Safety profile: IV NAD+ infusion is generally tolerated but produces dose-dependent infusion-related side effects including nausea, chest pressure, abdominal cramping, flushing, and lightheadedness. These are managed by slowing the infusion rate. Serious adverse events are rare but the compounded-IV regulatory pathway provides less FDA oversight than FDA-approved drugs, meaning lot-to-lot variation, sterility, and dose accuracy depend on the specific compounding pharmacy.

Cost comparison: at monthly IV NAD+ infusion ($200–$500/session), the annual cost is $2,400–$6,000. At weekly IV NAD+ infusion, the annual cost is $10,400–$26,000. For the SAME budget, a patient could afford brand Wegovy or Zepbound at cash prices ($1,000–$1,350/month, $12,000–$16,200/year) with documented 15–21% TBWL efficacy. The cost-effectiveness comparison is unfavorable for IV NAD+ at every realistic dosing schedule.

For our breakdown of GLP-1 cash and compounded pricing across US pharmacy channels, see our GLP-1 pricing index.

6. Safety, side effects, and drug interactions

Oral NMN and NR safety in published trials:

• Dellinger 2017 (PMID 29184669, NRPT 8 weeks): safe and well-tolerated in 120 healthy adults.
• Martens 2018 (PMID 29599478, NR 1,000 mg/day, 6 weeks): safe and well-tolerated in 30 healthy middle-aged and older adults.
• Dollerup 2018 (PMID 29992272, NR 2,000 mg/day, 12 weeks): safe and well-tolerated in 40 obese, insulin-resistant men.
• Yoshino M 2021 (PMID 33888596, NMN 250 mg/day, 10 weeks): safe and well-tolerated in 25 prediabetic postmenopausal women.
• Irie 2020 (PMID 31685720, NMN single dose pharmacokinetics): safe at 100, 250, and 500 mg single doses in healthy Japanese men.

Commonly reported side effects at studied doses: nausea, mild GI discomfort, flushing (more common with higher-dose NR at 1,000–2,000 mg/day), headache, fatigue. Most resolve with continued use or dose reduction.

Long-term safety: not well-characterized in published evidence. The longest published RCTs of NR supplementation are 12 weeks (Dollerup 2018); the longest NMN RCTs are 10 weeks (Yoshino M 2021). Multi-year safety, cumulative dose effects, and rare adverse events that emerge only in larger populations or over years are not addressed by current evidence.

Drug interactions: no specific NMN/NR drug interactions have been documented in peer-reviewed published evidence. NAD+ precursors do not appear to inhibit major CYP450 enzymes at studied doses. However, the relative paucity of interaction studies means the absence of evidence is not evidence of absence. Patients on any prescription medication should discuss NAD+ supplementation with their prescribing clinician before starting.

Theoretical concerns warranting caution:

• Cancer history: NAD+ supports PARP-mediated DNA repair, which is generally beneficial but is also a target of cancer chemotherapy (PARP inhibitors). Patients with active cancer or recent cancer history should defer NAD+ supplementation pending oncologist guidance.
• Pregnancy and breastfeeding: safety in pregnancy is not established. Avoid.
• Kidney disease: niacin and high-dose nicotinamide are metabolized through pathways relevant to renal clearance. Patients with significant CKD should discuss with nephrology before high-dose NAD+ precursor use.

IV NAD+ safety: generally tolerated when infused slowly. Common infusion-related effects: nausea, chest pressure, abdominal cramping, flushing, lightheadedness, anxiety. Managed by slowing the infusion rate. Rare serious adverse events have been reported in case literature. Compounded IV NAD+ preparations sit in a regulatory gray zone with less FDA oversight than FDA-approved drugs — sterility, dose accuracy, and lot-to-lot variation depend on the specific compounding pharmacy.

FDA regulatory context: the FDA's November 2022 NDI/IND-exclusion ruling on NMN is a regulatory determination based on the order of drug-investigation authorization versus dietary-supplement marketing — not a safety signal. NR remains available as a dietary supplement. The NIH Office of Dietary Supplements Niacin Fact Sheet covers the broader niacin / nicotinamide / NMN / NR family and notes that high-dose niacin (≥ 500 mg/day) can cause flushing, GI upset, and at chronic high doses hepatotoxicity — the same caveats partially apply to the NAD+ precursor family.

7. NAD+ and GLP-1: is there a published interaction?

No peer-reviewed published interaction study between NAD+ precursors and any GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide) exists in PubMed as of 2026-05-15.No published safety signal has been documented in either direction. The mechanisms are non-overlapping at the cellular level:

• NAD+ precursors act on intracellular NAD+ pools, sirtuin activity, and mitochondrial metabolism.
• GLP-1 receptor agonists act on cell-surface GLP-1 receptors, primarily in pancreatic islets, brainstem, and gut, affecting insulin secretion, gastric emptying, and appetite signaling.

Theoretically, adding an NAD+ precursor to a GLP-1 regimen should not produce a pharmacokinetic interaction. Whether it adds any clinical benefit is a separate question:

• GLP-1 receptor agonists alone produce 15–21% TBWL over 68–72 weeks. Adding a supplement with no documented independent weight-loss effect is unlikely to meaningfully enhance these results.
• For lean-mass preservation during rapid GLP-1 weight loss, the best-evidenced interventions are adequate protein (1.2–1.6 g/kg/day) plus resistance training — not NAD+ supplementation. See our semaglutide and muscle mass loss and exercise pairing on a GLP-1 articles for the evidence base.
• The dollar cost of NAD+ supplementation ($40–$120/mo oral, $200–$500/session IV) competes with the cost of the GLP-1 itself. For most patients, those dollars are better spent on the GLP-1 medication or on complete-protein dietary support.

Practical recommendation: if you are on a GLP-1 receptor agonist for weight management, focus the adjunct budget on adequate complete-protein intake, resistance training, and adherence to the GLP-1 itself. Adding NAD+ supplementation is unlikely to enhance the GLP-1 effect and currently lacks supporting evidence.

8. What actually causes meaningful weight loss

Evidence-based weight loss requires a combination of interventions, scaled to the patient's starting weight, BMI, comorbidities, and access:

(1) Sustained caloric deficit. A daily energy deficit of 500–750 kcal/day produces approximately 1 lb (0.45 kg) of weight loss per week. This is the foundation. No supplement substitutes for it.

(2) Adequate dietary protein. 1.2–1.6 g/kg body weight per day per ACSM and ISSN guidelines, distributed across 3–4 meals, preserves lean mass during weight loss. A 150-lb (68 kg) adult needs 82–109 g of protein daily, typically from complete protein sources (eggs, meat, fish, dairy, soy, legumes, whey).

(3) Exercise. At least 250 minutes per week of moderate aerobic activity (per ACSM 2009 position stand) plus 2+ days of resistance training (per ACSM 2011 and HHS 2018 Physical Activity Guidelines) for clinically significant weight loss with lean-mass preservation.

(4) FDA-approved anti-obesity medications for qualifying patients (BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease):

• Wegovy (semaglutide 2.4 mg weekly injection): ~15% TBWL in STEP-1 (Wilding 2021, PMID 33567185, NEJM) over 68 weeks
• Zepbound (tirzepatide 5/10/15 mg weekly injection): ~21% TBWL at 15 mg in SURMOUNT-1 (Jastreboff 2022, PMID 35658024, NEJM) over 72 weeks
• Saxenda (liraglutide 3 mg daily injection): 5–8% TBWL
• Foundayo (orforglipron oral): the first oral once-daily GLP-1 small molecule with FDA approval for chronic weight management. See our Foundayo overview.
• Older oral options: phentermine, phentermine/topiramate (Qsymia), bupropion/naltrexone (Contrave), orlistat (Xenical/Alli).

(5) Bariatric surgery for BMI ≥ 40, or BMI ≥ 35 with comorbidity, who haven't achieved sufficient response to medication. ASMBS-credentialed procedures (Roux-en-Y gastric bypass, sleeve gastrectomy) produce 25–35% TBWL durably.

NAD+ supplementation does not contribute to any of these mechanisms with peer-reviewed support. The dollars and attention spent on NAD+ products would, in almost every patient's case, produce better weight-loss outcomes if redirected to FDA-approved interventions.

9. FDA and FTC positions on supplement weight-loss claims

FDA position on NAD+ specifically:

• NMN November 2022 NDI/IND-exclusion ruling: the FDA determined that nicotinamide mononucleotide is excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(ii) of the Federal Food, Drug, and Cosmetic Act, because NMN had been authorized for investigation as a new drug before being marketed as a dietary supplement. Practical effect: NMN cannot be lawfully sold as a dietary supplement in the US.
• NR: Niagen (ChromaDex) holds NDI notification status and GRAS self-affirmation. NR remains commercially available.
• IV NAD+ infusion: not FDA-approved for any indication. Compounded IV NAD+ preparations are not FDA-approved drugs and are regulated under compounding-pharmacy frameworks (section 503A or 503B of the FD&C Act depending on facility status).
• Weight-loss claims for NAD+ products: the FDA has not specifically named NAD+ in its Tainted Weight Loss Products list, but the marketing patterns (“metabolism boost,” “fat oxidation,” “longevity weight management”) match the red-flag claim patterns highlighted in the FDA 2024 Consumer Update “Beware of Products Promising Miracle Weight Loss.”

FTC position on supplement weight-loss claims:

The FTC's 2024 Health Products Compliance Guidance restates the agency's long-standing position that health claims for supplements (including weight-loss claims) must be supported by “competent and reliable scientific evidence” — typically defined as randomized, controlled, human clinical trials at relevant doses, durations, and populations. Claims that exceed underlying evidence are considered deceptive under Section 5 of the FTC Act and are actionable.

The FTC's enforcement history includes multi-million-dollar settlements against supplement marketers for unsupported weight-loss claims (POM Wonderful, Sensa, garcinia cambogia products, green coffee bean extract). Marketers of NAD+ products that claim weight loss, fat oxidation, or metabolism enhancement without supporting RCT evidence operate in the same regulatory territory.

NIH Office of Dietary Supplements: the ODS Niacin Fact Sheet covers the broader B3 family (niacin / nicotinamide / NMN / NR) and addresses dosing, safety, and evidence base. The fact sheet notes that high-dose niacin can produce flushing, GI upset, and chronic-dose hepatotoxicity — safety considerations relevant to the NAD+ precursor family at the upper end of commercial dosing.

Consumer takeaway: when evaluating NAD+ product claims, apply the FDA red-flag-phrase framework. Claims like “guaranteed weight loss,” “burns fat,” “boosts metabolism,” “works without diet or exercise,” or “lose pounds in weeks” should trigger skepticism. The underlying published trials — Yoshino M 2021, Martens 2018, Dollerup 2018 — consistently report no significant weight change. The marketing claims exceed the evidence.

10. FAQ